Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy

Next Previous
Trial Profile

A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apraglutide (Primary) ; Corticosteroids; Ruxolitinib
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Acronyms STARGAZE
  • Sponsors Ironwood Pharmaceuticals; VectivBio

Most Recent Events

  • 14 Jan 2025 Status changed from active, no longer recruiting to discontinued, due to company decision.
  • 13 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
  • 28 Mar 2024 According to an Ironwood Pharmaceuticals media release, additional data from this STARGAZE trial are expected to be presented at an upcoming medical congress. This study will continue through its two-year endpoint, where apraglutide will be re-evaluated for safety and efficacy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top